GC
CRSP icon

Garde Capital’s CRISPR Therapeutics CRSP Stock Holding History

Garde Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-250
Closed -$12.2K – 372
2025
Q2 		$12.2K Hold
250
– – ﹤0.01% 489
2025
Q1 		$8.51K Buy
+250
New +$10.6K ﹤0.01% 503
2021
Q4 		– Sell
-916
Closed -$103K – 289
2021
Q3 		$103K Buy
916
+11
+1% +$1.38K 0.01% 272
2021
Q2 		$147K Buy
905
+56
+7% +$6.81K 0.02% 233
2021
Q1 		$103K Buy
+849
New +$128K 0.01% 254

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Garde Capital's CRSP Position: Q3 2025 in Review

Garde Capital sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 250 shares — an estimated $12.2K sold.

Garde Capital first reported a position in CRSP in Q1 2021 and held it in 5 quarters. The position peaked at $147K in Q2 2021. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Garde Capital reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Garde Capital sold 250 CRISPR Therapeutics shares in Q3 2025, an estimated $12.2K.
  • Garde Capital first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 5 quarters.
  • Garde Capital's CRISPR Therapeutics position peaked at $147K in Q2 2021.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.